MedTrace Logo

Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA)

NCT05056389 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-09-30

No results posted yet for this study

Summary

Feasibility study regarding 20 Patients with peritoneal metastases from colorectal cancer treated with cytoreductive surgery and HIPEC and subsequently with 4 courses of normothermic intraperitoneal chemotherapy - long term (NIPEC-OXA) with oxaliplatin.

Conditions

  • Peritoneal Metastases
  • Colo-rectal Cancer

Interventions

DRUG

Oxaliplatin

Administration of oxaliplatin intraperitoneally

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Mariusz Goscinski, MD.PhD. · Oslo University Hospital, The Norwegian Radium Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-17
Primary Completion
2023-03-31
Completion
2023-06-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05056389 on ClinicalTrials.gov